FDA Questions Safety Of J&J, Bayer’s Xarelto

Law360, New York (September 6, 2011, 6:21 PM EDT) -- Voicing concerns about the effectiveness and safety of Johnson & Johnson and Bayer HealthCare LLC’s blood thinner Xarelto, U.S. Food and Drug Administration staff declined to recommend approval for the drug in a report released Tuesday.

The staff recommended a so-called complete response in briefing information about the rivaroxaban tablets prepared for the Cardiovascular and Renal Drugs Advisory Committee, which is poised to consider J&J's new drug application during its meeting on Thursday.

The company wants the FDA to approve the use of the drug to...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.